Delcath Systems, Inc. Message Board
-
you need a chemostat treatment in your brain
-
how much more
-
16-0
-
people cashing out
-
I believe they had their shot, its time to cash out
sorry for your loss -
I am sorry for you but I at one point had very high hopes
its over now, sadly -
keep play a losing game until it goes to zero, now that's a great plan
-
out there
they have no concept of how to present a device -
total loss
-
be no stock to split, it will be zero
-
for those holding on... I hope you like the color pink...sheets
-
at was a long ride some 10 years but they are a complete failure with the presentation and product
I would sell at this point
there is nothing left here to save but the few pennies left in the stock -
to file for a drug with the fda
dcth is a lost cause -
how can the panel approve anything when the FDA has stated dcth needs a new trial?
At best they will get a refuse to accept the application to approve the device. has anyone thought this through?
what can the panel review? all we have is gen 1 trial data. we are back to square 1.
dcth has to raise more cash and start all over again.
I see this going much lower as the stock gets diluted with new massive stock offerings. -
by 1000 delays
sell this #$%$ -
I sold and lost money lucky to be out at a $1
these guys have been doing this for 25 years and that is a quarter century missing the mark
you have to be nuts to invest in deathcath at this point -
wrong on just about every dcth call- brought us all right down the toilet
-
stick a fork in it, this pig is well done
-
the stock is toast
-
hepatic progression free survival (hPFS), the BAC-cross over arm of the study was consistent with the hPFS achieved in patients randomized directly to the chemosaturation arm. Furthermore, the study showed that crossover from BAC to the chemosaturation arm led to a median overall survival benefit of 11 months compared to treatment with BAC alone.
Sentiment: Buy